Consensus Insulet Corporation

Stocks

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
149.01 ^USD	+0.60%		+5.61%	-47.58%

10-12	Insulet Launches Omnipod Discover Platform Across US	MT
10-12	Insulet Corporation Announces U.S. Full Market Release of Omnipod Discover	CI

Evolution of the Average Target: Insulet Corporation

Evolution of the Target Price: Insulet Corporation

Changes in Analyst Recommendations: Insulet Corporation

3e0524047b880e412460a89.djY0N6_rOQAWq6VOqjR4NUFQJRMnETw5E3QLDrvzC9c.N1VVBPrGFFRT-pUc8kdBdBM9dEBMUgsAJiBhX-mgeZEaUwEB_Y9LcHTy7A~4c3510d51a2e9fbd20798bc15072fcce

Analysts' recommendations: Insulet Corporation

10-12	Analyst recommendations: GoDaddy, HubSpot, Microsoft, Palantir, T-Mobile…
10-09	Leerink Partners Adjusts Insulet Price Target to $143 From $145	MT
09-28	Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says	MT
08-06	Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says	MT
08-06	Jefferies & Co. Adjusts Insulet Price Target to $275 From $360	MT
08-06	Stifel Nicolaus Adjusts Insulet Price Target to $180 From $225	MT
08-06	TD Cowen Adjusts Insulet Price Target to $144 From $294	MT
08-06	Baird Adjusts Insulet Price Target to $175 From $248	MT
08-06	Rothschild & Co Redburn Adjusts Insulet Price Target to $165 From $220	MT
08-06	Bernstein Adjusts Insulet Price Target to $175 From $200	MT
08-06	Raymond James Adjusts Insulet Price Target to $180 From $216	MT
08-06	Benchmark Company Adjusts Insulet Price Target to $185 From $250	MT
08-06	Citigroup Adjusts Insulet Price Target to $150 From $172	MT
08-06	UBS Adjusts Insulet Price Target to $150 From $174, Maintains Neutral Rating	MT
08-06	RBC Capital Adjusts Price Target on Insulet to $160 From $245, Maintains Outperform Rating	MT
08-06	Leerink Partners Downgrades Insulet to Market Perform From Outperform, Adjusts PT to $145 From $247	MT
08-06	Deutsche Bank Adjusts Insulet Price Target to $180 From $190, Maintains Buy Rating	MT
08-06	Truist Downgrades Insulet to Hold From Buy, Adjusts Price Target to $153 From $210	MT
08-06	BTIG Downgrades Insulet to Neutral From Buy	MT
08-06	JPMorgan Downgrades Insulet to Neutral From Overweight, Adjusts PT to $152 From $275	MT
08-06	Wells Fargo Downgrades Insulet to Equalweight From Overweight, Adjusts PT to $144 From $255	MT
08-06	Oppenheimer Downgrades Insulet to Market Perform From Outperform	MT
08-05	Citigroup Cuts Insulet Price Target to $150 From $172	MT
08-05	Piper Sandler Adjusts Price Target on Insulet to $160 From $210	MT
07-28	UBS Downgrades Insulet to Neutral From Buy, Lowers Price Target to $174 From $400	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INSULET CORPORATION					+12.19%
	ABBOTT LABORATORIES					+14.41%
	STRYKER CORPORATION					+18.06%
	MEDTRONIC PLC					+9.65%
	ESSILORLUXOTTICA					+19.16%
	CENCORA, INC.					+11.51%
	HOYA CORPORATION					+17.34%
	BECTON, DICKINSON AND COMPANY					-1.68%
	IDEXX LABORATORIES, INC.					+24.56%
	ALCON INC.					+29.13%
	Average					+15.43%
	Weighted average by Cap.					+14.86%